Announcements
- Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
- Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
- Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
- Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
- Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- Akero Therapeutics Announces Pricing of Public Offering of Common Stock
- Akero Therapeutics Announces Proposed Public Offering of Common Stock
More ▼
Key statistics
On Monday, Akero Therapeutics Inc (0K4:STU) closed at 22.67, 111.87% above the 52 week low of 10.70 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.67 |
---|---|
High | 22.67 |
Low | 22.67 |
Bid | 21.28 |
Offer | 21.37 |
Previous close | 22.84 |
Average volume | 0.00 |
---|---|
Shares outstanding | 69.15m |
Free float | 58.77m |
P/E (TTM) | -- |
Market cap | 1.58bn USD |
EPS (TTM) | -3.20 USD |
Data delayed at least 15 minutes, as of Jun 17 2024.
More ▼